Marco is Managing Director of Rare Partners since its foundation in March 2010. He collaborates as a consultant with Pharmaceutical Companies, with Investment Funds and with Research Organizations since 1996, focusing his activity in the areas of Research & Development.
Prior to this he rose to Research & Development Director at Fidia Research Laboratories during a 15-year career (1981-1996) with the company. Marco has more than 35 years of experience in R&D, gained in Academic Institutions (University of Padova and Thomas Jefferson University) and in companies, including CM&D Pharma, PharmEste and Angelini Ricerche.
He has been member of the scientific board of several biotech companies and collaborates with public and private institutions for the review of scientific projects and business plans. Marco is author of more than 120 papers, 200 abstracts and several patents, on cardiovascular and autonomic pharmacology, both at preclinical and clinical level.
Since 2010 Marco has been particularly active in the field of rare diseases and orphan drugs, gaining experience in the field of Orphan Drug Designations, of Protocol and Scientific Advice and of relationships with Regulatory Authorities in particular. Furthermore, his activity in the field of grant applications allowed development of research projects up the level of clinical trials.
Marco holds a degree in Pharmacy from the University of Padova.